Redx Pharma

RXC008 nominated as GI-ROCK drug candidate

Lighthouse | 30 March 2022

Share this note

  • Redx Pharma has selected RXC008 as a development candidate in its novel GI-targeted ROCK programme. This will become the second Redx-discovered ROCK (Rho Associated Coiled-Coil Containing Protein Kinase) programme to enter the clinic after RXC007. ROCK is an exciting clinically validated target that sits at a nodal point in a cell signalling pathway, where it modulates inflammatory response and fibrotic processes.
  • There are two kinase forms, ROCK1 and ROCK2, that are involved in the development of fibrosis in multiple organs including the lungs, heart, liver, kidneys, and gut. However, the inhibition of ROCK1 is associated with cardiovascular toxicities; hence the systemically acting RXC007, currently completing Phase I trials in IPF (idiopathic pulmonary fibrosis), acts selectively on ROCK2.
  • RXC008 is pan-ROCK inhibitor selected designed to only work locally in the gut wall and, as it is quickly degraded by metabolic enzymes, to have a short half-life. This should avoid the systemic side-effects that are associated with simultaneous inhibition of ROCK1 and ROCK2 yet retain the impressive efficacy seen in preclinical models, where both prophylactic (preventative) and therapeutic (reversal) effects were noted.
  • The clinical programme will focus on Crohn’s disease, where up to half of patients can develop significant fibrosis that leads to stricture formation. The only real treatment for such fibrostenotic disease currently is surgery, but the recurrence rate is high. Clinical success with RXC008 would be genuinely transformational for this sizeable patient population.
  • RXC008 is Redx Pharma’s third development candidate that addresses fibrosis indications. RXC007 is an in-house programme completing Phase I trials, with a Phase IIa safety and tolerability study in IPF with and without standard of care (SoC) expected to start in 2022. AZN5055, previously known as RXC006, is a potent small molecule of the Porcupine receptor in development by AstraZeneca for fibrosis indications. This was out-licensed, on attractive terms, at the preclinical stage.

Trinity Delta view: The selection of RXC008 is another reminder of the quality of Redx Pharma’s discovery platform. It is the strength of its medicinal chemistry expertise, where it has proven its ability to solve complex targeting issues, that underpins the investment case. RXC008 highlights the aim to create either best-in-class or first-in-class small molecules addressing clear needs in oncology and fibrotic diseases. Redx Pharma has a well-balanced clinical pipeline, with a mix of in-house and partnered programmes. This should provide a stream of news flow over the next 12-18 months as development progresses. Our rNPV model, based on conservative assumptions, generates a £434m ($564.7m) valuation, equivalent to 157.5p/share.


30 March 2022

Market Cap£204.8m
Primary exchangeAIM London
Company CodeREDX
Corporate clientYes

Company description

Redx Pharma specialises in the discovery and development of small molecule therapeutics, with an emphasis on oncology and fibrotic diseases. It aims to initially progress them through proof-of-concept studies, before evaluating options for further development and potential value creation.


Lala Gregorek
+44 (0) 20 3637 5043

Franc Gregori
+44 (0) 20 3637 5041


Trinity Delta Research Limited (“TDRL”; firm reference number: 725161), which trades as Trinity Delta, is an appointed representative of Equity Development Limited (“ED”). The contents of this report, which has been prepared by and is the sole responsibility of TDRL, have been reviewed, but not independently verified, by ED which is authorised and regulated by the FCA, and whose reference number is 185325.

ED is acting for TDRL and not for any other person and will not be responsible for providing the protections provided to clients of TDRL nor for advising any other person in connection with the contents of this report and, except to the extent required by applicable law, including the rules of the FCA, owes no duty of care to any other such person. No reliance may be placed on ED for advice or recommendations with respect to the contents of this report and, to the extent it may do so under applicable law, ED makes no representation or warranty to the persons reading this report with regards to the information contained in it.

In the preparation of this report TDRL has used publicly available sources and taken reasonable efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee or warranty as to the accuracy or completeness of the information or opinions contained herein, nor to provide updates should fresh information become available or opinions change.

Any person who is not a relevant person under section of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom should not act or rely on this document or any of its contents. Research on its client companies produced by TDRL is normally commissioned and paid for by those companies themselves (‘issuer financed research’) and as such is not deemed to be independent, as defined by the FCA, but is ‘objective’ in that the authors are stating their own opinions. The report should be considered a marketing communication for purposes of the FCA rules. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. TDRL does not hold any positions in any of the companies mentioned in the report, although directors, employees or consultants of TDRL may hold positions in the companies mentioned. TDRL does impose restrictions on personal dealings. TDRL might also provide services to companies mentioned or solicit business from them.

This report is being provided to relevant persons to provide background information about the subject matter of the note. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information that we provide is not intended to be, and should not in any manner whatsoever be, construed as personalised advice. Self-certification by investors can be completed free of charge at TDRL, its affiliates, officers, directors and employees, and ED will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits.

Copyright 2022 Trinity Delta Research Limited. All rights reserved.